"Houston Eye Associates (HEA) is a team of board-certified ophthalmologists and board-licensed optometrists with advanced fellowship and specialty training in the fields of ophthalmology and optometry. For 50 years Houston Eye has been providing patients with the highest level of care at over 21 locations in Greater Houston. HEA covers all areas of ophthalmological and optometric care, with treatment available in all specialties and ages. Specialties include: LASIK/refractive surgery, cataracts, glaucoma, retina, oculoplastic, uveitis and neuro-ophthalmology. HEA also has an optical center that specializes in vison correction with state-of-the-art ophthalmic lenses and custom contact lenses. Houston Eye Associates is more than just eye exams"

During the past decade, Houston Eye Associates conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 15 clinical trials were completed, i.e. on average, 40.5% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 14 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Houston Eye Associates" #1 sponsor was "Aerie Pharmaceuticals" with 3 trials, followed by "Bausch & Lomb Incorporated" with 3 trials sponsored, "Kala Pharmaceuticals, Inc." with 3 trials sponsored, "Shire" with 3 trials sponsored and "Allergan" with 3 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Houston Eye Associates" #1 collaborator was "ActualEyes Inc." with 1 trials as a collaborator, "Boston Children's Hospital" with 1 trials as a collaborator, "IQVIA Biotech" with 1 trials as a collaborator, "Novartis" with 1 trials as a collaborator and "Stada Arzneimittel AG" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Houston Eye Associates" are "Cataract" (5 trials), "Diabetic Macular Edema" (3 trials), "Dry Eye Syndromes" (3 trials), "Keratoconjunctivitis Sicca" (3 trials) and "Adenoviral Conjunctivitis" (2 trials). Many other conditions were trialed in "Houston Eye Associates" in a lesser frequency.

Most popular intervention types in "Houston Eye Associates" are "Drug" (33 trials), "Other" (7 trials), "Device" (4 trials), "Biological" (3 trials) and "Combination Product" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "SHP640" (3 trials), "APP13007, 0.05%" (2 trials), "KPI-121 0.25% Ophthalmic Suspension" (2 trials) and "Luminopia One" (2 trials). Other intervention names were less common.

The vast majority of trials in "Houston Eye Associates" are 44 trials for "All" genders.

Currently, there are NaN active trials in "Houston Eye Associates". undefined are not yet recruiting, 6 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Houston Eye Associates, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Houston Eye Associates, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".